Niusule expands Chinese distribution
This article was originally published in The Tan Sheet
Executive SummaryU.S. nutraceutical supplement manufacturer Niusule Biotech extends its distribution in China through an agreement with China Nepstar Chain Drugstore Ltd., the country's largest chain. As of Aug. 25, Nepstar will distribute Niusule's Gummy Bear supplement through its 55 stores in Hangzhou, and in the future will distribute the product through chain's network in Shanghai, Ninbo, Tianjing and Suzhou. Monrovia, Calif.-based Niusule previously distributed to 226 outlets in Zhejiang province, Shanghai and Beijing
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2019.